Stock CASI CASI PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

CASI Pharmaceuticals, Inc. Stock

Equities

CASI

KYG1933S1012

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-07-05 pm EDT 		5-day change 1st Jan Change
5.73 USD +9.14% Intraday chart for CASI Pharmaceuticals, Inc. +4.18% -19.97%
Jun. 27 Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data MT
Jun. 27 US Futures Trend Lower Pre-Bell as Investors Await Slew of Economic Data MT

Financials (USD)

Sales 2024 * 19.8M Sales 2025 * 46.48M Capitalization 74.43M
Net income 2024 * -35M Net income 2025 * -33M EV / Sales 2024 * 3.76 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.6 x
P/E ratio 2024 *
-2.24 x
P/E ratio 2025 *
-2.69 x
Employees 176
Yield 2024 *
-
Yield 2025 *
-
Free-Float 62.32%
More Fundamentals * Assessed data

Chart CASI Pharmaceuticals, Inc.

Dynamic Chart

Latest news about CASI Pharmaceuticals, Inc.

Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data MT
US Futures Trend Lower Pre-Bell as Investors Await Slew of Economic Data MT
Top Premarket Gainers MT
CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company CI
Wei-Wu He proposed to acquire Business Operations in China and all license-in, distribution and related rights in Asia from CASI Pharmaceuticals, Inc. for $40 million. CI
CASI Pharmaceuticals Receives Acquisition Proposal for its Entire China Business CI
CASI Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from VR Adviser, LLC, Foresite Capital Management, LLC, Panacea Venture Management Co., Ltd. CI
Sector Update: Health Care Stocks Advance in Afternoon Trading MT
CASI Pharmaceuticals Gets FDA Clearance For Blood Disorder Study MT
CASI Pharmaceuticals Receives FDA Clearance on the Investigational New Drug Application for CID-103 in Immune Thrombocytopenia CI
Earnings Flash (CASI) CASI PHARMACEUTICALS Posts Q1 Revenue $3.4M, vs. Street Est of $12M MT
CASI Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Top Midday Gainers MT
Looming Employment Report, Powell Testimony Stifle US Equity Futures Pre-Bell MT
More news

Analyst Recommendations on CASI Pharmaceuticals, Inc.

HC Wainwright Raises Price Target on CASI Pharmaceuticals to $12 From $10, Keeps Buy Rating MT
BTIG Adjusts CASI Pharmaceuticals' Price Target to $10 From $21, Keeps Buy Rating MT
CORRECTION : BTIG Lowers CASI Pharmaceuticals' Price Target to $21 From $40, Buy Rating Kept MT
HC Wainwright Lowers CASI Pharmaceuticals' Price Target to $12 From $30, Buy Rating Maintained MT
Oppenheimer Adjusts CASI Pharmaceuticals' Price Target to $35 From $6 After Reverse Stock Split, Maintains Outperform Rating MT
More recommendations

Press releases CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company PR
CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He PR
CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP) PR
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS PR
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS PR
More press releases

Quotes and Performance

1 day+9.14%
1 week+4.18%
Current month+4.18%
1 month+63.25%
3 months+79.06%
6 months-13.96%
Current year-19.97%
More quotes

Highs and lows

1 week
4.96
Extreme 4.96
5.74
1 month
2.61
Extreme 2.61
5.74
Current year
2.05
Extreme 2.05
8.19
1 year
1.90
Extreme 1.9
8.48
3 years
1.45
Extreme 1.45
17.40
5 years
1.45
Extreme 1.45
39.00
10 years
1.45
Extreme 1.45
88.92
More quotes

Managers and Directors - CASI Pharmaceuticals, Inc.

Managers TitleAgeSince
Wei Wu He CEO
 Chief Executive Officer 59 19-04-01
Wei Zhang DFI
 Director of Finance/CFO 64 18-08-31
Chun Hua Wang COO
 Chief Operating Officer 52 16-12-31
Members of the board TitleAgeSince
Wei Wu He CEO
 Chief Executive Officer 59 19-04-01
Yue Wu BRD
 Director/Board Member 62 13-03-31
Zhen Bo Su BRD
 Director/Board Member 48 23-03-20
More insiders

Quotes

Date Price Change Volume
24-07-05 5.73 +9.14% 97,216
24-07-03 5.25 -2.96% 36,968
24-07-02 5.41 +0.19% 86,578
24-07-01 5.4 -1.82% 257,145
24-06-28 5.5 +12.24% 810,683

Delayed Quote Nasdaq, July 05, 2024 at 04:30 pm EDT

More quotes

Company Profile

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
Sector
Pharmaceuticals
Calendar
2024-08-08 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for CASI Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
5.73 USD
Average target price
6 USD
Spread / Average Target
+4.71%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CASI PHARMACEUTICALS, INC. Stock CASI Pharmaceuticals, Inc.
-19.97% 74.43M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+56.89% 823B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+39.52% 627B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.55% 353B
ABBVIE INC. Stock AbbVie Inc.
+7.92% 295B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.74% 239B
NOVARTIS AG Stock Novartis AG
+13.83% 220B
ROCHE HOLDING AG Stock Roche Holding AG
-0.49% 219B
AMGEN INC. Stock Amgen Inc.
+7.94% 167B
PFIZER, INC. Stock Pfizer, Inc.
-2.57% 159B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CASI Stock